Frankfurt
29.09.26 | 08:05
1,122 Euro
-0,18 % -0,002
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15:45 | Orexo AB: Orexo resubmits NDA for IZIPRY to the FDA, a high-dose rescue medication for opioid overdose | 99 | GlobeNewswire (Europe) | IZIPRY is based on Orexo's world-class AmorphOX® drug delivery platform and is designed to reverse overdoses involving highly potent synthetic opioids such as fentanylThe NDA resubmission addresses... ► Artikel lesen | |
| 14.09. | Orexo AB: Orexo Announces FDA Acceptance of Investigational New Drug (IND) Application for OX640 for the Treatment of Anaphylaxis | 143 | GlobeNewswire (Europe) | FDA accepts IND application for OX640 for the treatment of anaphylaxis, enabling initiation of pivotal clinical development program Needle-free epinephrine intranasal powder candidate developed using... ► Artikel lesen | |
| OREXO Aktie jetzt für 0€ handeln | |||||
| 01.09. | Orexo AB: Fredrik Järrsten resigns as CFO of Orexo AB | 152 | GlobeNewswire (Europe) | Uppsala, Sweden, September 1st, 2026 - Orexo AB (publ.) (STO: ORX) (OTCQX: ORXOY) today announced that Fredrik Järrsten has resigned from his position as Chief Financial Officer (CFO) and will leave... ► Artikel lesen | |
| 01.09. | Orexo reaches non-binding agreement in principle to settle investigation by US Department of Justice | 401 | PR Newswire | UPPSALA, Sweden, Sept. 1, 2026 /PRNewswire/ -- Orexo AB (publ) (STO: ORX) (OTCQX: ORXOY) today announced that the company has reached a non-binding agreement in principle on the main elements... ► Artikel lesen | |
| 31.08. | Orexo AB: Orexo reaches non-binding agreement in principle to settle investigation by US Department of Justice | 205 | GlobeNewswire (Europe) | Uppsala, Sweden - August 31st 2026 - Orexo AB (publ) (STO: ORX) (OTCQX: ORXOY) today announced that the company has reached a non-binding agreement in principle on the main elements of a settlement... ► Artikel lesen | |
| 16.07. | Orexo weitet Verlust im zweiten Quartal aus - Umsatz verfehlt die Schätzungen | 1 | Investing.com Deutsch | ||
| 16.07. | Orexo AB: Orexo Q2 2026 Interim Report | 229 | GlobeNewswire (Europe) | Building momentum for the next chapterFinancial summary April - JuneTotal net revenues of SEK 3.5 m (4.8)Net earnings for the period is SEK -102.5 m (-97.5)Cash flow for the period is SEK -109.3 m (2.2)Earnings... ► Artikel lesen | |
| 09.06. | Orexo AB: Orexo appoints Raheleh Nassaji as SVP Business Development, strengthening its focus on new partnerships | 232 | GlobeNewswire (Europe) | Uppsala, Sweden - June 9, 2026 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announced that the company is strengthening its business development efforts through the appointment of Raheleh Nassaji... ► Artikel lesen | |
| 19.05. | Orexo announces positive outcome from an in-vivo study of OX390 | 880 | PR Newswire | UPPSALA, Sweden, May 19, 2026 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces positive data from a pre-clinical in-vivo study on the nasal absorption of atipamezole... ► Artikel lesen | |
| 19.05. | Orexo AB: Orexo announces positive outcome from an in-vivo study of OX390 | 230 | GlobeNewswire (Europe) | Uppsala, Sweden - May 19, 2026 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces positive data from a pre-clinical in-vivo study on the nasal absorption of atipamezole when delivered with... ► Artikel lesen | |
| 07.05. | Orexo AB: Report from Orexo AB's annual general meeting May 7 2026 | 374 | GlobeNewswire (Europe) | Election of the board of directors and auditorThe annual general meeting in Orexo AB (publ) on 7 May 2026 resolved, in accordance with the nomination committee's proposal, that the number of board members... ► Artikel lesen | |
| 28.04. | Orexo AB: Orexo Q1 2026 Interim Report | 190 | GlobeNewswire (Europe) | Well positioned to advance pipeline to value inflection pointsFinancial summary January - MarchTotal net revenues of SEK 5.0 m (13.2)Net earnings for the period is SEK -105.2 m (-90.6)Cash flow for... ► Artikel lesen | |
| 06.03. | Invitation & Agenda: Orexo R&D Day on March 24 | 415 | PR Newswire | UPPSALA, Sweden, March 6, 2026 /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&D Day on March 24, 2026. The... ► Artikel lesen | |
| 06.03. | Orexo changes the organizational structure and management team to increase focus on development of new products | 587 | PR Newswire | UPPSALA, Sweden, March 6, 2026 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces changes to its organizational structure and management... ► Artikel lesen | |
| 06.03. | Orexo AB: Orexo changes the organizational structure and management team to increase focus on development of new products | 246 | GlobeNewswire (Europe) | Uppsala, Sweden - March 6, 2026 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces changes to its organizational structure and management team. The changes are a result of the divestment of... ► Artikel lesen | |
| 19.02. | Orexo AB: Orexo: Conversion of Class C shares into ordinary shares and conveyance of ordinary shares within the framework of long-term performance-based incentive programs | 471 | GlobeNewswire (Europe) | The Board of Orexo AB (publ) has today decided to convert 416,417 Class C shares into ordinary shares and to subsequently convey 416,417 ordinary shares to certain participants in the long-term incentive... ► Artikel lesen | |
| 05.02. | Orexo AB: Orexo Interim Report Q4 2025, incl. Full Year Report | 891 | GlobeNewswire (Europe) | Turning a transformative deal into new opportunitiesQ4 2025 highlights›Dexcel Pharma USA aquired all rights to Zubsolv® US on December 31, at a purchase price of USD 91 m plus the value of inventory... ► Artikel lesen | |
| 22.12.25 | Orexo AB: Orexo Enters Into Agreement with Dexcel Pharma USA to Divest US Rights to Zubsolv | 783 | GlobeNewswire (Europe) | · An asset purchase agreement has been signed with Dexcel Pharma USA, which will acquire the full rights to Zubsolv® in the US, at a purchase price of USD 91 million plus the value of inventory at closing... ► Artikel lesen | |
| 23.10.25 | Orexo AB: Orexo Q3 2025 Interim Report | 297 | GlobeNewswire (Europe) | Unlocking the potential of the AmorphOX® technologyQ3 2025 highlights› Total net revenues of SEK 118.7 m (136.5)› EBITDA of SEK -9.8 m (-0.7), including a negative impact from costs associated with... ► Artikel lesen | |
| 01.10.25 | Orexo AB: Orexo strengthens innovation and research with move to new premises | 334 | GlobeNewswire (Europe) | Uppsala, Sweden, October 1, 2025 - Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY) is taking the next step in its development journey by relocating to new, modern premises in Uppsala Science Park. The move... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AURORA CANNABIS | 3,556 | -1,06 % | Aurora Cannabis Inc.: Aurora Cannabis Files Application with Alberta Securities Commission to Protect Company Shareholders Having Identified Several Deficiencies in Curaleaf's Hostile Bid Disclosure | NASDAQ | TSX: ACB
Aurora has filed an application with the Alberta Securities Commission for an order requiring Curaleaf to comply with securities laws.
Aurora intends to demonstrate... ► Artikel lesen | |
| ABBVIE | 232,60 | -0,77 % | Zwei Dividendenmaschinen mit rund 6 % Rendite: Warum Johnson & Johnson und AbbVie jetzt ins Depot gehören könnten | Zwei etablierte US-Healthcare-Konzerne bieten derzeit eine Dividendenrendite um 6 %, robustes Wachstum und defensive Geschäftsmodelle. Auf Seeking Alpha werden Johnson & Johnson sowie AbbVie als besonders... ► Artikel lesen | |
| TILRAY BRANDS | 3,510 | -0,85 % | Tilray Brands, Inc.: BrewDog Builds Momentum for Next Growth Chapter with Expanded Senior Leadership Team | New appointments strengthen marketing, hospitality, category, and international commercial leadership as BrewDog advances long-term growth under Tilray BrandsELLON, Scotland and LONDON, Sept. 28, 2026... ► Artikel lesen | |
| BRISTOL-MYERS SQUIBB | 55,78 | -0,76 % | Bristol-Myers Squibb Company: Care Within Reach: How the Bristol Myers Squibb Foundation Is Strengthening Health Systems Across Africa | Originally published by the Bristol Myers Squibb Foundation NORTHAMPTON, MA / ACCESS Newswire / September 28, 2026 / Francis Kwoba is a 68-year-old retired policeman from Bungoma County, Kenya. During... ► Artikel lesen | |
| TEVA PHARMACEUTICAL INDUSTRIES | 34,000 | +1,19 % | Teva Pharmaceutical Industries Ltd: Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA (denosumab-adet), a Biosimilar to Xgeva (denosumab) | DEGEVMA is now FDA-approved across all indications of the reference product, Xgeva (denosumab), to help prevent bone complications in adults with advanced cancer that has spread to the bone, for the... ► Artikel lesen | |
| BAUSCH HEALTH | 4,998 | -1,61 % | Bausch Health Companies Inc.: Bausch Health and YUN Announce Expansion to Mexico and Across Additional EMEA Markets | Collaboration expands access to science-led, microbiome-friendly skincare solutions in Mexico and across new markets in EMEA, including launches in the Czech Republic, Slovakia, Ukraine,... ► Artikel lesen | |
| BIONANO GENOMICS | 1,750 | +4,17 % | Bionano Genomics: Bionano Announces Hiring of Chief Scientific Officer | SAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a leader in genome analysis solutions, today announced the appointment of Alex Hastie, Ph.D., as its Chief Scientific... ► Artikel lesen | |
| OPKO HEALTH | 1,440 | +0,70 % | OPKO Health, Inc.: OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests | MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the expansion of its financing relationship with HealthCare Royalty, a business of KKR (HCRx), through... ► Artikel lesen | |
| JAGUAR HEALTH | 5,510 | -8,47 % | Jaguar Health, Inc.: Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting | Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS-IF for crofelemer powder for oral solution... ► Artikel lesen | |
| KEENOVA THERAPEUTICS | - | - | Keenova Therapeutics: Keenova Advances Podiatry Pipeline with First Patient Dosed in Phase 3 Trial of XIAFLEX (collagenase clostridium histolyticum) for Hammer Toe | First registered, randomized Phase 3 trial evaluating the efficacy, safety, and tolerability of XIAFLEX in adults with hammer toe
No FDA-approved nonsurgical... ► Artikel lesen | |
| AVALO THERAPEUTICS | 13,360 | +0,60 % | Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress | ||
| BAYER | 48,880 | -3,78 % | Biotech: Übernahmen und Blockbuster stehen im Raum! Im Rampenlicht tauchen immer wieder Novo Nordisk, BioNxt und Bayer auf | Der Sturm geht weiter! Der BioTech-Sektor steht vor einer massiven Welle von Übernahmen und der Zulassung neuer Blockbuster-Medikamente. Im Rampenlicht stehen derzeit vor allem die Sektoren der Gewichtsreduktion... ► Artikel lesen | |
| MERCK KGAA | 137,40 | -0,76 % | Merck Aktie | Wichtige Durchschnittslinien durchbrochen | Analyse | ||
| NOVO NORDISK | 33,580 | -0,58 % | Kampf um Abnehmpille - Novo Nordisk schließt Milliarden-Deal mit China | ||
| PFIZER | 24,980 | -1,19 % | Pfizer vor Neubewertung? Warum die Gewinnschätzungen der Wall Street und der Aktienkurs auseinanderlaufen | Pfizer könnte vor einer Neubewertung stehen: Die aktuellen Konsensschätzungen der Analysten signalisieren eine deutliche Ergebnisdynamik, während der Aktienkurs diese Perspektive nach Einschätzung eines... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OREXO AB finden Sie auf Wallstreet Online.